

2020

INFORMATION ON JAPANESE REGULATORY AFFAIRS

*Regulatory Information Task Force
Japan Pharmaceutical Manufacturers Association*

**Pharmaceutical
Administration and
Regulations in Japan**

Japan Pharmaceutical Manufacturers Association

2020

<http://www.jpma.or.jp/about/issue/gratis/index2.html> (Japanese)

<http://www.jpma.or.jp/english/parj/whole.html> (English)

Pharmaceutical Administration and Regulations in Japan

This file contains information concerning pharmaceutical administration, regulations, and new drug development in Japan updated annually by the English RA Information Task Force, International Affairs Committee, Japan Pharmaceutical Manufacturers Association (JPMA). The contents are not abstracts of governmental rules or regulations but concise descriptions of most current practices by regulatory agencies and the industry that the working group complies. The file does not contain anything related to forecasts. The file is available also at the homepage of National Institute of Health Sciences (<http://www.nihs.go.jp/kanren/iyaku.html>).

Japan Pharmaceutical Manufacturers Association

<http://www.jpma.or.jp/english/>

Table of Contents

CHAPTER 1 1

ORGANIZATION AND FUNCTION OF THE MINISTRY OF HEALTH, LABOUR AND WELFARE 1

| | |
|---|---|
| 1. PHARMACEUTICAL SAFETY AND ENVIRONMENTAL HEALTH BUREAU (PSEHB)..... | 2 |
| 1.1 General Affairs Division..... | 2 |
| 1.2 Pharmaceutical Evaluation Division... | 2 |
| 1.3 Medical Device Evaluation Division ... | 2 |
| 1.4 Pharmaceutical Safety Division | 3 |
| 1.5 Compliance and Narcotics Division ... | 3 |
| 1.6 Blood and Blood Products Division.... | 4 |
| 2. HEALTH POLICY BUREAU | 4 |
| 2.1 Economic Affairs Division..... | 4 |
| 2.2 Research and Development Division..... | 4 |
| 3. NATIONAL INSTITUTE OF HEALTH SCIENCES | 5 |
| 4. PHARMACEUTICALS AND MEDICAL DEVICES AGENCY, AN INDEPENDENT ADMINISTRATIVE ORGANIZATION | 5 |
| 4.1 Office of Review Administration | 6 |
| 4.2 Office of Review Management..... | 6 |
| 4.3 Office of New Drug I..... | 6 |
| 4.4 Office of New Drug II..... | 6 |
| 4.5 Office of New Drug III..... | 6 |
| 4.6 Office of New Drug IV | 7 |
| 4.7 Office of New Drug V | 7 |
| 4.8 Office of Cellular and Tissue-based Products | 7 |
| 4.9 Office of Vaccines and Blood Products | 7 |
| 4.10 Office of OTC/Quasi-drugs..... | 7 |
| 4.11 Office of Generic Drugs..... | 7 |
| 4.12 Office of Non-clinical and Clinical Compliance | 7 |
| 4.13 Office of Medical Devices I..... | 7 |
| 4.14 Office of Medical Devices II..... | 7 |
| 4.15 Office of Standards and Compliance for Medical Devices..... | 8 |
| 4.16 Office of In Vitro Diagnostics..... | 8 |
| 4.17 Office of Manufacturing Quality and Vigilance for Medical Devices | 8 |
| 4.18 Office of Manufacturing Quality for Drugs..... | 8 |
| 4.19 Office of Informatics and Management for Safety..... | 8 |
| 4.20 Office of Pharmacovigilance I | 8 |
| 4.21 Office of Pharmacovigilance II | 8 |

| | |
|---|----|
| 4.22 Office of International Programs..... | 8 |
| 4.23 Office of International Cooperation..... | 8 |
| 4.24 Office of Advanced Evaluation with Electronic Data | 9 |
| 4.25 Office of Medical Informatics and Epidemiology | 9 |
| 4.26 Kansai Branch | 9 |
| 4.27 Hokuriku Branch | 9 |
| 5. NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (NIBIOHN)..... | 9 |
| 6. JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT (AMED)..... | 9 |
| 7. PHARMACEUTICAL AFFAIRS AND FOOD SANITATION COUNCIL (PAFSC)..... | 9 |
| 8. NATIONAL INSTITUTE OF INFECTIOUS DISEASES | 10 |

CHAPTER 2.....15

PHARMACEUTICAL LAWS AND REGULATIONS

.....15

| | |
|--|----|
| 1. PHARMACEUTICAL LAWS..... | 15 |
| 2. PHARMACEUTICAL AND MEDICAL DEVICE ACT..... | 15 |
| 3. OUTLINE OF PHARMACEUTICAL REGULATIONS | 17 |
| 3.1 Definition of Drugs | 17 |
| 3.2 Classification of Drugs..... | 17 |
| 3.3 License for Manufacturing/Marketing Businesses | 19 |
| 3.4 License for Manufacturing Business and Accreditation of Overseas Manufacturers | 20 |
| 3.5 Manufacturing/Marketing Approvals | 22 |
| 3.6 Good Manufacturing Practice (GMP)..... | 22 |
| 3.7 Drug Master File (MF) | 23 |
| 3.8 Drug Retail Seller Licensing | 24 |
| 3.9 Labeling and Package Inserts | 24 |
| 3.10 Proper Advertisement | 25 |
| 3.11 Good Laboratory Practice (GLP)..... | 26 |
| 3.12 Good Clinical Practice (GCP)..... | 26 |
| 3.13 Trial Conducted from a Compassionate Viewpoint (expanded trial)..... | 27 |
| 3.14 Patient-requested Therapy System | 28 |
| 3.15 Good Post-marketing Study Practice (GPSP) | 28 |
| 3.16 Reexamination..... | 28 |
| 3.17 Reevaluation..... | 29 |
| 3.18 Adverse Drug Reaction (ADR) and Infection Reporting | 29 |
| 3.19 Risk Management Plan (RMP)..... | 29 |
| 3.20 Dissemination of Information | 30 |

| | | | | | |
|------|--|----|---|--|-----|
| 3.21 | Measures related to the Law Concerning Access to Information Held by Administrative Organizations | 30 | 6.4 | Safety Measures against Bovine Spongiform Encephalitis (BSE) | 49 |
| 3.22 | Patent System | 31 | | | |
| 3.23 | Drug Abuse Control | 32 | | | |
| 3.24 | Countermeasures for Counterfeit Prescription Drug | 33 | | | |
| 4. | MARKETING APPROVALS | 33 | CHAPTER 3 | 57 | |
| 4.1 | Drug Marketing Approvals | 33 | | | |
| 4.2 | Marketing Approval Reviews | 33 | | | |
| 4.3 | Manufacturing/Marketing Approval Application with Electronic Data | 35 | | | |
| 4.4 | Priority Review System and Designation of Drug Products for Priority Reviews | 36 | DRUG DEVELOPMENT | 57 | |
| 4.5 | Restrictive Approval System | 37 | 1. | PROCESS FROM DEVELOPMENT TO APPROVAL | 57 |
| 4.6 | Orphan Drugs | 37 | 1.1 | Development of New Drugs | 57 |
| 4.7 | Drugs for Pediatric Use | 37 | 1.2 | Procedures for Clinical Trials | 58 |
| 4.8 | Unapproved Drugs and Drugs of Off-label Use | 38 | 1.3 | Safety information on Adverse Reactions and Infections during the Study | 60 |
| 4.9 | Packaging Strategy for World-first Products | 39 | 1.4 | Interview advice meetings | 61 |
| 4.10 | Regulatory Science Strategy Consultations for Regenerative Medicine Products (former Regulatory Strategy Consultations) . | 40 | 1.5 | Approval review | 65 |
| 4.11 | Approval System Implemented to Promote the Application of Regenerative Medicine Including Cellular and Tissue-Based Products for Commercialization (Approval with Conditions and Time Limit) | 41 | 1.6 | Compliance review | 66 |
| 4.12 | Conditional Accelerated Approval System for Pharmaceuticals | 41 | 1.7 | GMP compliance inspection | 67 |
| 4.13 | Guidelines for Promoting Optimal Use | 41 | 2. | DATA REQUIRED FOR APPROVAL APPLICATIONS | 70 |
| 4.14 | Biosimilar Products | 42 | 2.1 | Data to be Attached to Approval Application of Drugs | 73 |
| 4.15 | Combination Products | 42 | 3. | GUIDELINES CONCERNING DRUG APPROVAL APPLICATIONS | 74 |
| 4.16 | Codevelopment | 43 | 3.1 | Quality and Nonclinical Studies | 75 |
| 4.17 | Transfer of Marketing Approvals | 43 | 3.2 | Clinical Studies | 79 |
| 4.18 | Approval Applications for Drugs Manufactured Overseas | 44 | 4. | OTHER | 88 |
| 4.19 | Issuing of Certificates for Exported Drugs by MHLW | 44 | 4.1 | Biotechnological Products | 88 |
| 5. | JAPANESE PHARMACOPOEIA AND OTHER STANDARDS | 45 | 4.2 | Drugs Using Materials of Human or Animal Origin as Ingredients (Biological Products) | 88 |
| 5.1 | Japanese Pharmacopoeia (JP) | 45 | 4.3 | Biosimilar Products | 89 |
| 5.2 | Standards Based on Article 42 of the Pharmaceutical and Medical Device Act | 46 | 4.4 | Public Disclosure of Information on New Drug Development | 90 |
| 5.3 | Standards for Biological Materials ... | 47 | 4.5 | ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) | 91 |
| 5.4 | Quality Standards Based on Notifications | 48 | | | |
| 5.5 | Government Batch Test | 48 | CHAPTER 4 | 116 | |
| 6. | PHARMACEUTICAL SUPERVISION | 48 | | | |
| 6.1 | Pharmaceutical Supervision | 48 | POST-MARKETING SURVEILLANCE OF DRUGS | 116 | |
| 6.2 | Product Recalls | 48 | 1. | GVP | 119 |
| 6.3 | Prevention of Medical Accidents Caused by Drugs, etc | 49 | 2. | GPSP | 126 |
| | | | 3. | PAPER COMPLIANCE REVIEW AND ON-SITE GPSP SURVEYS OF DATA FOR REEXAMINATION AND REEVALUATION | 130 |
| | | | 4. | ADVERSE DRUG REACTIONS AND INFECTIONS REPORTING SYSTEM | 130 |
| | | | 4.1 | Adverse Drug Reaction and Infectious Disease Reporting System by Pharmaceutical | |

| | |
|--|-----|
| Companies | 130 |
| 4.2 Drug and Medical Device Safety Information Reporting System by Medical Personnel..... | 133 |
| 4.3 Reporting of Adverse Drug Reactions from Patients | 134 |
| 4.4 WHO International Drug Monitoring Program..... | 134 |
| 5. PERIODIC INFECTION REPORTS FOR BIOLOGICAL PRODUCTS (ARTICLE 68-14 AND 68-24 IN THE LAW) | 135 |
| 6. REEXAMINATION SYSTEM (ARTICLE 14-4 AND 23-29 OF THE PHARMACEUTICAL AFFAIRS LAW)..... | 135 |
| 6.1 Designation for Reexamination of Drugs..... | 136 |
| 6.2 Periodic Safety Reports (Article 63 of the Enforcement Regulations of the Law)..... | 136 |
| 6.3 Data Required for Reexamination Applications and Reexamination Procedures | 137 |
| 7. REEVALUATION SYSTEM (ARTICLES 14-6 AND 23-31 OF THE LAW)..... | 138 |

CHAPTER 5 145

SUPPLY AND DISSEMINATION OF DRUG SAFETY MANAGEMENT INFORMATION 145

| | |
|---|-----|
| 1. PACKAGE INSERTS | 145 |
| 1.1 New Guidance on the Style and Format of Package Inserts | 147 |
| 1.2 Headings and Their Sequence in Package Inserts | 148 |
| 1.3 Precautions | 149 |
| 1.4 Labeling of Excipients | 150 |
| 1.5 Entries for Biological Products | 150 |
| 1.6 Brand Names of Prescriptions Drugs..... | 151 |
| 1.7 Consultation Works Related to Revision of Package Insert | 152 |
| 1.8 Information about English Package Insert | 152 |
| 2. INFORMATION TO SUPPLEMENT PACKAGE INSERTS | 152 |
| 2.1 Outline of Prescription Pharmaceutical Product Information | 153 |
| 2.2 Pharmaceutical Interview Forms (IF)..... | 153 |
| 2.3 Commentaries on "Precautions" in Package Inserts of New Drugs | 154 |
| 3. SUPPLY AND DISSEMINATION OF SAFETY MANAGEMENT INFORMATION..... | 154 |
| 3.1 Distribution of Emergency Safety Information (Yellow Letters) | 155 |

| | |
|--|-----|
| 3.2 Safety Flash Report (Blue Letters) . | 156 |
| 3.3 Commentaries on "Precautions" in Package Inserts of New Drugs | 157 |
| 3.4 Distribution of Information by 'Notices of Revision of Precautions' | 157 |
| 3.5 Dissemination of Information for Drugs That Have Completed Reexamination or Reevaluation | 158 |
| 3.6 Dissemination of ADR Information by the Pharmaceuticals and Medical Devices Safety Information (Information on Adverse Reactions to Drugs) | 158 |
| 3.7 Dissemination of Information by Drug Safety Update | 158 |
| 3.8 Medical Guides for Patients..... | 159 |
| 3.9 Manual for Handling Disorders due to Adverse Drug Reactions..... | 159 |
| 4. ELECTRONIC INFORMATION DISSEMINATION..... | 159 |
| 5. PACKAGE INSERTS OF NON-PRESCRIPTION DRUGS | 160 |
| 6. PACKAGE INSERTS OF GUIDANCE-MANDATORY DRUGS | 160 |

CHAPTER 6.....166

HEALTH INSURANCE PROGRAMS AND DRUG PRICING IN JAPAN.....166

| | |
|--|-----|
| 1. HISTORY OF HEALTH INSURANCE PROGRAMS | 166 |
| 2. MEDICAL BENEFITS OFFERED UNDER HEALTH INSURANCE PROGRAMS | 167 |
| 3. REIMBURSEMENT OF MEDICAL FEES . | 167 |
| 4. NATIONAL HEALTH INSURANCE PRICE LIST | 168 |
| 5. PRICING FORMULA FOR REIMBURSEMENT PRICE REVISIONS OF DRUGS LISTED IN THE NHI PRICE LIST | 168 |
| 6. RECENT REVISIONS OF THE NHI PRICE LIST | 170 |
| 7. DETERMINATION OF REIMBURSEMENT PRICES FOR NEW DRUGS | 171 |
| 8. ENTRY OF GENERIC DRUGS IN THE NHI PRICE LIST | 172 |
| 9. ISSUES RELATED TO THE USE OF DETERMINATION OF UNAPPROVED DRUGS AND OFF-LABEL USE | 172 |

Pharmaceutical Regulations in Japan:

| | | | | | |
|----------|--|-----|----------|--|-----|
| Fig. 1 | Organization of Ministry of Health, Labour, and Welfare (Health-related organizations only)..... | 11 | Fig. 17 | Reevaluation System | 144 |
| Fig. 2 | Organization of Pharmaceutical Safety and Environmental Health Bureau (PSEHB) and Pharmaceuticals and Medical Devices Agency (PMDA)..... | 12 | Fig. 18 | Layout of Package Insert Based on Revised Guidelines for Preparation (Image) | 162 |
| Fig. 3 | Organization of the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)..... | 14 | Fig. 19 | Standard Procedures for Revision of Package Insert at PMDA (1) | 164 |
| Fig. 4 | Flowchart of Patent-Life Extension | 51 | Fig. 20 | Standard Procedures for Revision of Package Insert at PMDA (2) | 165 |
| Fig. 5 | Flowchart of Approval Review..... | 52 | Fig. 21 | Reimbursement Pricing Flow-sheet for New Drugs | 174 |
| Fig. 6 | Procedure for manufacturing and marketing approval of drugs for overseas manufacturers in Japan..... | 53 | Fig. 22 | Correlation between the Time of Marketing Approval Based on Pharmaceutical Affairs Law and the Time of Entry in the NHI Price List | 175 |
| Fig. 7 | Flowchart of Drug Listing in Japanese Pharmacopoeia | 54 | Table 14 | History of Reimbursement Price Revisions | 176 |
| Table 1 | List of Main Controlled Substances..... | 55 | Table 15 | Annual Changes in Drug Expenses and Estimated Divergence Rate | 178 |
| Table 2 | Divisions of the Pharmaceutical and Food Safety Bureau in Charge of Certification Work | 56 | Table 16 | Requirements for Applying Premiums | 186 |
| Fig. 8 | Flowchart of New Drug Development and Approval | 93 | | | |
| Fig. 9 | Timeline of the standard process of new drug approval (ordinary review products)... | 94 | | | |
| Fig. 10 | Timeline of the standard process of new drug approval (priority review products)..... | 95 | | | |
| Table 3 | Data to be Submitted with an Application for Approval to Manufacture/Market: A New Prescription Drug..... | 96 | | | |
| Table 4 | Data to be Submitted with an Application for a Non-prescription Drug | 98 | | | |
| Table 5 | Classification of Clinical Studies According to Objectives..... | 100 | | | |
| Table 6 | List of Major Guidelines, etc. on Physicochemical Properties, Specifications, and Tests Methods | 101 | | | |
| Table 7 | List of Major Guidelines, etc. on Toxicity Tests | 103 | | | |
| Table 8 | List of Major Guidelines, etc. on Pharmacological Studies..... | 104 | | | |
| Table 9 | List of Major Guidelines, etc. on Pharmacokinetic Studies..... | 104 | | | |
| Table 10 | List of Major Guidelines, etc. on Bioequivalence Studies..... | 105 | | | |
| Table 11 | List of Major Guidelines, etc. on Clinical Evaluation..... | 106 | | | |
| Table 12 | List of Major Guidelines, etc. Related to Biotechnology..... | 109 | | | |
| Fig. 11 | Organization of ICH Common Technical Documents | 110 | | | |
| Fig. 12 | Correlation between Development Phases and Types of Study..... | 111 | | | |
| Table 13 | ICH topics and guidelines - Progress of harmonization | 112 | | | |
| Fig. 13 | Pharmaceutical Post-marketing Surveillance System | 140 | | | |
| Fig. 14 | Post-marketing Collection and Reporting of Pharmaceutical Safety Information | 141 | | | |
| Fig. 15 | Collection and Reporting of Pharmaceutical Safety Information | 142 | | | |
| Fig. 16 | Reexamination System | 143 | | | |